Biolinq Shine FDA De Novo: Diabetes Wearable

Here’s a breakdown of ⁤the text, extracting key details and summarizing its⁣ content:

Overall Topic: The text ⁣discusses the Biolinq Shine, a ‍new biosensor ⁢designed to help manage metabolic health for people with non-insulin dependent ⁣Type 2⁢ Diabetes.

Key Points:

* Biolinq Shine: A first-of-its-kind biosensor that automatically tracks glucose levels,physical activity,and sleep. It’s designed for people with Type 2 Diabetes who don’t ‍use insulin.
* Benefits: Provides insights to encourage healthier choices and helps patients achieve better “time-in-range” (TIR) for glucose levels.
* Technology: Uses a shallow microsensor array (up to‍ 20x shallower than traditional sensors) and doesn’t require a needle⁢ for insertion.
* Type 2 Diabetes (T2D) Context: T2D accounts for 90-95% of diabetes cases in the US and impacts 63% globally.It’s characterized by hyperglycemia, insulin resistance, and often occurs with obesity, high blood pressure, and high lipid levels.
* Importance of TIR: The American Diabetes Association (ADA) recommends keeping glucose levels ⁣within the target range at least 70%⁢ of the time.
* Investor Confidence: Alpha ⁣Wave‍ Global, a long-term investor, is confident in Biolinq’s vision for biowearables and its potential to redefine cardiometabolic health.

In essence, the article is a promotional piece highlighting a new technology (Biolinq Shine) that aims to improve the management of Type 2 Diabetes by providing continuous, convenient glucose monitoring ⁢and actionable ‍insights.

Image Credit Information (from the JSON data):

* ⁤ Image‍ Credit: windynight
* Source: stock.adobe.com
* Link: https://stock.adobe.com/contributor/205585485/windynight?load_type=author&prev_url=detail

Superscript Citations:

* ‍ Superscript 1 is used multiple times, likely referencing a source ⁢about the Biolinq ‍Shine and the importance of TIR.
* Superscript 2⁤ and 3 are used to cite information about Type 2 Diabetes.